The TNFα/NFkB signalling pathway has been shown to make a vital role in tumour proliferation, metastasis and drug resistance, and in lung and breast cancer DTCs, activation of the NFkB signalling pathway has been reported and can be used as an early therapeutic target (83, 84). This evidence concerns the gene NFKB1 and breast carcinoma.